If accepted, Vifor Pharma's £23m offer will "claw back" money for the NHS and close the CMA's first-ever disparagement case.

Vifor Pharma has pledged to pay £23 million to the NHS after Britain’s competition watchdog raised concerns the drugs firm had been making misleading claims about the safety of a rival’s iron ...

All regulatory clearances received for the acquisition of Vifor Pharma AG; Settlement of the offer is scheduled for 9 August 2022; Seasoned biopharma executive, Hervé Gisserot, designated to lead ...

Nephrology products company Vifor Pharma is shelling out about $252 million combined up front to acquire Sanifit Therapeutics and Inositec, developers of drugs for a blood vessel complication ...

The European Commission has reached a deal with Vifor Pharma after it was accused of disparaging its only rival in the iron deficiency market.

Vifor Pharma has offered to launch a marketing campaign to address any damage caused by its criticisms of a rival to its key drug, EU regulators said on Friday, a move that could stave off a ...

In a move to diversify its business, Australian biopharma CSL has agreed to acquire Vifor Pharma for $11.7 billion. The deal would give CSL—heavily dependent on vaccines and blood plasma ...

Shares in Vifor Pharma AG rose sharply in opening trade Tuesday after receiving an offer from Australia’s CSL Ltd. that values the company at $11.7 billion. At 0812 GMT, shares in the Swiss ...

Vifor Pharma Group reported stable net sales and a continued strong increase in profitability in 2020, despite challenges to patient access from COVID-19 and the impact of a much stronger Swiss ...

Partnership brings together Vifor Pharma’ s world-class iron deficiency portfolio with Fresenius Kabi’ s market-leading patient access in China Gives Vifor Pharma access to largest iron ...

Vifor Pharma and Angion Biomedica Corp. (NASDAQ: ANGN) today announced that the phase-III trial of Angion’s ANG-3777 did not demonstrate a statistically significant difference from placebo on ...

Vifor Pharma's shares surged more than 15% in early trading on Monday after the Swiss drugmaker and Australia's CSL both confirmed they were talking about a potential merger.